Yılmaz, SüleymanÖktem, FatihKaraman, Emin2020-05-012020-05-0120100937-4477https://doi.org/10.1007/s00405-009-1165-7https://hdl.handle.net/20.500.12684/5503WOS: 000277939700006PubMed: 19946777Our aim was to investigate cisplatin ototoxicity with transient evoked otoacoustic emission (TEOAE) test before it is seen with pure tone audiometer. In our study, we compared the hearing of the patients who are receiving 100 mg/m(2) 4-cycle cisplatin for lung cancer, with pure tone audiometer and transient evoked otoacoustic emission test in 1,000, 2,000 and 4,000 Hz. We found 55% hearing decrease with pure tone audiometer in patients that are receiving 100 mg/m(2) 4-cycle cisplatin for lung cancer. We also established emission amplitude decrease with TEOAE test in 85% of the patients. When we compare the patients' pure tone audiometer in 1,000, 2,000 and 4,000 Hz and TEOAE amplitude changes we did not find statistically significant results (P > 0.05), but when we compare the patients' TEOAE amplitude changes in 1,000, 2,000 and 4,000 Hz with control group we found statistically significant results (P < 0.05). Our results show that cisplatin ototoxicity could be find out with TEOAE test before it is seen with pure tone audiometer.en10.1007/s00405-009-1165-7info:eu-repo/semantics/closedAccessCisplatinPure tone audiometerTransient evoked otoacoustic emissionArticle267710411044WOS:000277939700006Q1Q2